Citations (182)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
Omer F. Kuzu, Raghavendra Gowda, Arati Sharma, Mohammad A. Noory, Gregory Kardos, SubbaRao V. Madhunapantula, Joseph J. Drabick & Gavin P. Robertson. (2018) Identification of WEE1 as a target to make AKT inhibition more effective in melanoma. Cancer Biology & Therapy 19:1, pages 53-62.
Read now
Read now
Nicholas Burwick & Bertal H. Aktas. (2017) The eIF2-alpha kinase HRI: a potential target beyond the red blood cell. Expert Opinion on Therapeutic Targets 21:12, pages 1171-1177.
Read now
Read now
Joseph G Crompton, Madhusudhanan Sukumar & Nicholas P Restifo. (2016) Targeting Akt in cell transfer immunotherapy for cancer. OncoImmunology 5:9.
Read now
Read now
Gwenola Manic, Florine Obrist, Guido Kroemer, Ilio Vitale & Lorenzo Galluzzi. (2014) Chloroquine and hydroxychloroquine for cancer therapy. Molecular & Cellular Oncology 1:1.
Read now
Read now
Aung Naing. (2013) Overcoming resistance to mTOR inhibition for enhanced strategies in clinical trials. Expert Opinion on Investigational Drugs 22:6, pages 679-685.
Read now
Read now
Mari Iida, Toni M. Brand, David A. Campbell, Megan M. Starr, Neha Luthar, Anne M. Traynor & Deric L. Wheeler. (2013) Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab. Cancer Biology & Therapy 14:6, pages 481-491.
Read now
Read now
Mehrdad Dirin & Johannes Winkler. (2013) Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotides. Expert Opinion on Biological Therapy 13:6, pages 875-888.
Read now
Read now
Mary Leonard, Natasha Hill, Paula Bubulya & Madhavi Kadakia. (2013) The PTEN-Akt pathway impacts the integrity and composition of mitotic centrosomes. Cell Cycle 12:9, pages 1406-1415.
Read now
Read now
Weili Sun & Shakeel Modak. (2012) Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine. OncoTargets and Therapy 5, pages 21-29.
Read now
Read now
Francesca Buontempo, Francesca Chiarini, Daniela Bressanin, Giovanna Tabellini, Fraia Melchionda, Andrea Pession, Milena Fini, Luca M. Neri, James A. McCubrey & Alberto M. Martelli. (2012) Activity of the selective IκB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia. Cell Cycle 11:13, pages 2467-2475.
Read now
Read now
Shannon N. Westin & Russell R. Broaddus. (2012) Personalized therapy in endometrial cancer: Challenges and opportunities. Cancer Biology & Therapy 13:1, pages 1-13.
Read now
Read now
SubbaRao V. Madhunapantula, Paul J. Mosca & Gavin P. Robertson. (2011) The Akt signaling pathway. Cancer Biology & Therapy 12:12, pages 1032-1049.
Read now
Read now
Sheila A Doggrell. (2011) Lemur tyrosine kinase-3 (LMTK3) as a target in oestrogen positive breast cancer. Expert Opinion on Therapeutic Targets 15:12, pages 1419-1422.
Read now
Read now
Margrith E Mattmann, Sydney L Stoops & Craig W Lindsley. (2011) Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape. Expert Opinion on Therapeutic Patents 21:9, pages 1309-1338.
Read now
Read now
Daniel W Bowles & Antonio Jimeno. (2011) New phosphatidylinositol 3-kinase inhibitors for cancer. Expert Opinion on Investigational Drugs 20:4, pages 507-518.
Read now
Read now
Articles from other publishers (167)
Ava Safaroghli-Azar, Mohammad-Javad Sanaei, Atieh Pourbagheri-Sigaroodi & Davood Bashash. (2023) Phosphoinositide 3-kinase (PI3K) classes: From cell signaling to endocytic recycling and autophagy. European Journal of Pharmacology 953, pages 175827.
Crossref
Crossref
Shaowei Bing, Senfeng Xiang, Zhimei Xia, Yilong Wang, Zhonghai Guan, Jinxin Che, Aixiao Xu, Xiaowu Dong, Ji Cao, Bo Yang, Jinhu Wang, Qiaojun He & Meidan Ying. (2023) AKT inhibitor Hu7691 induces differentiation of neuroblastoma cells. Acta Pharmaceutica Sinica B 13:4, pages 1522-1536.
Crossref
Crossref
Peijun Zhu, Ting Li, Qingqing Li, Yawen Gu, Yuan Shu, Kaibo Hu, Leifeng Chen, Xiaogang Peng, Jie Peng & Liang Hao. (2022) Mechanism and Role of Endoplasmic Reticulum Stress in Osteosarcoma. Biomolecules 12:12, pages 1882.
Crossref
Crossref
Hikari YoshitaneKiyomichi ImamuraTakenori OkuboYuta OtobeSatoshi KawakamiShunsuke ItoToru TakumiKazuki HattoriIsao NaguroHidenori IchijoYoshitaka Fukada. (2022) mTOR-AKT Signaling in Cellular Clock Resetting Triggered by Osmotic Stress. Antioxidants & Redox Signaling 37:10-12, pages 631-646.
Crossref
Crossref
Matteo Trudu, Laura Oliva, Ugo Orfanelli, Alessandra Romano, Francesco Di Raimondo, Francesca Sanvito, Maurilio Ponzoni & Simone Cenci. (2022) Preclinical evidence of a direct pro-survival role of arginine deprivation in multiple myeloma. Frontiers in Oncology 12.
Crossref
Crossref
Sisi Liu, Yaxin Li, Jin Wang, Xue Rui, Haobo Tian, Chenshuo Li & Chunyan Guo. (2022)
In Silico
Studies of Piperidine Derivatives as Protein Kinase B Inhibitors
through 3D-QSAR, Molecular Docking and Molecular Dynamics Simulation
. Letters in Drug Design & Discovery 19:7, pages 591-605.
Crossref
Crossref
Jetta Sandeep Kumar, Gangireddy Sujeevan Reddy, Raghavender Medishetti, Kazi Amirul Hossain, B. Thirupataiah, Jhansi Edelli, Shilpak Dilip Bele, Rebecca Kristina Edwin, Alex Joseph, Gautham G. Shenoy, C. Mallikarjuna Rao & Manojit Pal. (2022) Ultrasound assisted one-pot synthesis of rosuvastatin based novel azaindole derivatives via coupling–cyclization strategy under Pd/Cu-catalysis: Their evaluation as potential cytotoxic agents. Bioorganic Chemistry 124, pages 105857.
Crossref
Crossref
Saketh S. Dinavahi, Yu-Chi Chen, Kishore Punnath, Arthur Berg, Meenhard Herlyn, Momeneh Foroutan, Nicholas D. Huntington & Gavin P. Robertson. (2022) Targeting WEE1/AKT Restores p53-Dependent Natural Killer–Cell Activation to Induce Immune Checkpoint Blockade Responses in “Cold” Melanoma. Cancer Immunology Research 10:6, pages 757-769.
Crossref
Crossref
Xufen Yu, Jia Xu, Yudao Shen, Kaitlyn M. Cahuzac, Kwang-su Park, Brandon Dale, Jing Liu, Ramon E. Parsons & Jian Jin. (2022) Discovery of Potent, Selective, and In Vivo Efficacious AKT Kinase Protein Degraders via Structure–Activity Relationship Studies. Journal of Medicinal Chemistry 65:4, pages 3644-3666.
Crossref
Crossref
Alexey Ponomarev, Zarema Gilazieva, Valeriya Solovyeva, Cinzia Allegrucci & Albert Rizvanov. (2022) Intrinsic and Extrinsic Factors Impacting Cancer Stemness and Tumor Progression. Cancers 14:4, pages 970.
Crossref
Crossref
Benoîte Mery, Coralie Poulard, Muriel Le Romancer & Olivier Trédan. (2021) Targeting AKT in ER-Positive HER2-Negative Metastatic Breast Cancer: From Molecular Promises to Real Life Pitfalls?. International Journal of Molecular Sciences 22:24, pages 13512.
Crossref
Crossref
Jetta Sandeep Kumar, Gangireddy Sujeevan Reddy, Raghavender Medishetti, Aramita Ray, Shilpak Dilip Bele, Kazi Amirul Hossain, B. Thirupataiah, Rebecca Kristina Edwin, Parameswar Behera, Alex Joseph, Gautham G. Shenoy, C. Mallikarjuna Rao & Manojit Pal. (2021) Sonochemical synthesis of rosuvastatin based novel 3-methyleneisoindolin-1-one derivatives as potential anticancer agents. Journal of Molecular Structure 1240, pages 130574.
Crossref
Crossref
Dimitrios T. Trafalis, Sofia Sagredou, Panayiotis Dalezis, Maria Voura, Stella Fountoulaki, Nikolaos Nikoleousakos, Konstantinos Almpanakis, Maria V. Deligiorgi & Vasiliki Sarli. (2021) Anticancer Activity of Triazolo-Thiadiazole Derivatives and Inhibition of AKT1 and AKT2 Activation. Pharmaceutics 13:4, pages 493.
Crossref
Crossref
Marian Rofeal & Fady Abd El-Malek. (2020) Valorization of Lipopeptides Biosurfactants as Anticancer Agents. International Journal of Peptide Research and Therapeutics 27:1, pages 447-455.
Crossref
Crossref
Ross S. Mancini, Christopher J. Barden, Donald F. Weaver & Mark A. Reed. (2021) Furazans in Medicinal Chemistry. Journal of Medicinal Chemistry 64:4, pages 1786-1815.
Crossref
Crossref
Pietro Asproni, Francesca Millanta, Lorenzo Ressel, Fabio Podestà, Francesca Parisi, Iacopo Vannozzi & Alessandro Poli. (2021) An Immunohistochemical Study of the PTEN/AKT Pathway Involvement in Canine and Feline Mammary Tumors. Animals 11:2, pages 365.
Crossref
Crossref
Md. Junaid, Yeasmin Akter, Syeda Samira Afrose, Mousumi Tania & Md. Asaduzzaman Khan. (2021) Biological Role of AKT and Regulation of AKT Signaling Pathway by Thymoquinone: Perspectives in Cancer Therapeutics. Mini-Reviews in Medicinal Chemistry 21:3, pages 288-301.
Crossref
Crossref
Motoyasu Saji, Caroline S. Kim, Chaojie Wang, Xiaoli Zhang, Tilak Khanal, Kevin Coombes, Krista La Perle, Sheue-Yann Cheng, Philip N. Tsichlis & Matthew D. Ringel. (2020) Akt isoform-specific effects on thyroid cancer development and progression in a murine thyroid cancer model. Scientific Reports 10:1.
Crossref
Crossref
Jetta Sandeep Kumar, B. Thirupataiah, Raghavender Medishetti, Aramita Ray, Shilpak Dilip Bele, Kazi Amirul Hossain, Gangireddy Sujeevan Reddy, Rebecca Kristina Edwin, Alex Joseph, Nitesh Kumar, Gautham G. Shenoy, C. Mallikarjuna Rao & Manojit Pal. (2020) Rosuvastatin based novel 3-substituted isocoumarins / 3-alkylidenephthalides: Ultrasound assisted synthesis and identification of new anticancer agents. European Journal of Medicinal Chemistry 201, pages 112335.
Crossref
Crossref
Loral Showalter, Brian J. Czerniecki & Gary K. Koski. (2020)
Th1 cytokines in conjunction with pharmacological Akt inhibition potentiate apoptosis of breast cancer cells
in vitro
and suppress tumor growth
in vivo
. Oncotarget 11:30, pages 2873-2888.
Crossref
Crossref
Nne E. Uko, Osman F. Güner, Diane F. Matesic & J. Phillip Bowen. (2020) Akt Pathway Inhibitors. Current Topics in Medicinal Chemistry 20:10, pages 883-900.
Crossref
Crossref
Danica Sims, Hapiloe Mabaruti Maranyane, Victoria Damerell, Dhirendra Govender, Ashwin W. Isaacs, Jade Peres & Sharon Prince. (2020) The c-Myc/AKT1/TBX3 Axis Is Important to Target in the Treatment of Embryonal Rhabdomyosarcoma. Cancers 12:2, pages 501.
Crossref
Crossref
Meshach Asare-Werehene, Kiran Nakka, Arkadiy Reunov, Chen-Tzu Chiu, Wei-Ting Lee, Mohammad R. Abedini, Pei-Wen Wang, Dar-Bin Shieh, F. Jeffrey Dilworth, Euridice Carmona, Tien Le, Anne-Marie Mes-Masson, Dylan Burger & Benjamin K. Tsang. (2019) The exosome-mediated autocrine and paracrine actions of plasma gelsolin in ovarian cancer chemoresistance. Oncogene 39:7, pages 1600-1616.
Crossref
Crossref
Claudio ScuoppoJiguang WangMirjana PersaudSandeep K. MittanKatia BassoLaura PasqualucciRaul RabadanGiorgio InghiramiCarla GrandoriFrancesc BoschRiccardo Dalla-Favera. (2019) Repurposing dasatinib for diffuse large B cell lymphoma. Proceedings of the National Academy of Sciences 116:34, pages 16981-16986.
Crossref
Crossref
Xiao-Fei Liu, Jing-Wei Li, Hong-Zhi Chen, Zi-Yuan Sun, Guang-Xi Shi, Jian-Min Zhu, Ai-Li Song, Ying Wang & Xiang-Qi Li. (2019) Yanghe Huayan decoction inhibits the capability of trans-endothelium and angiogenesis of HER2+ breast cancer via pAkt signaling. Bioscience Reports 39:2.
Crossref
Crossref
Bapurao Sudam Lad & Sreenivas Katukojvala. (2018) Piano-Stool Rhodium Enalcarbenoids: Application to Catalyst-Controlled Metal-Templated Annulations of Diazoenals and 1,3-Dicarbonyls. ACS Catalysis 8:12, pages 11807-11814.
Crossref
Crossref
Roghayyeh Vakili‐Ghartavol, Reza Mombeiny, Arash Salmaninejad, Seyed Mahdi Rezayat Sorkhabadi, Reza Faridi‐Majidi, Mahmoud Reza Jaafari & Hamed Mirzaei. (2018) Tumor‐associated macrophages and epithelial–mesenchymal transition in cancer: Nanotechnology comes into view. Journal of Cellular Physiology 233:12, pages 9223-9236.
Crossref
Crossref
Devki Nandan, Naixin Zhang, Yi Yu, Brian Schwartz, Stella Chen, Peter E. Kima & Neil E. Reiner. (2018) Miransertib (ARQ 092), an orally-available, selective Akt inhibitor is effective against Leishmania. PLOS ONE 13:11, pages e0206920.
Crossref
Crossref
Parag P. Patwardhan, Elgilda Musi & Gary K. Schwartz. (2018) Preclinical Evaluation of Nintedanib, a Triple Angiokinase Inhibitor, in Soft-tissue Sarcoma: Potential Therapeutic Implication for Synovial Sarcoma. Molecular Cancer Therapeutics 17:11, pages 2329-2340.
Crossref
Crossref
George Nitulescu, Maryna Van De Venter, Georgiana Nitulescu, Anca Ungurianu, Petras Juzenas, Qian Peng, Octavian Olaru, Daniela Grădinaru, Aristides Tsatsakis, Dimitris Tsoukalas, Demetrios Spandidos & Denisa Margina. (2018) The Akt pathway in oncology therapy and beyond (Review). International Journal of Oncology.
Crossref
Crossref
Bo Jiang, Yan Guan, Hui-juan Shen, Lin-hui Zhang, Jun-xia Jiang, Xin-wei Dong, Hua-hao Shen & Qiang-min Xie. (2018) Akt/PKB signaling regulates cigarette smoke-induced pulmonary epithelial-mesenchymal transition. Lung Cancer 122, pages 44-53.
Crossref
Crossref
Mahmoud A. Al-Sha’er & Mutasem O. Taha. (2018) Ligand-based modeling of Akt3 lead to potent dual Akt1/Akt3 inhibitor. Journal of Molecular Graphics and Modelling 83, pages 153-166.
Crossref
Crossref
Noémie Emeriau, Marie de Clippele, Philippe Gailly & Nicolas Tajeddine. (2018) Store operated calcium entry is altered by the inhibition of receptors tyrosine kinase. Oncotarget 9:22, pages 16059-16073.
Crossref
Crossref
Saketh S. Dinavahi, Mohammad A. Noory, Raghavendra Gowda, Joseph J. Drabick, Arthur Berg, Rogerio I. Neves & Gavin P. Robertson. (2018) Moving Synergistically Acting Drug Combinations to the Clinic by Comparing Sequential versus Simultaneous Drug Administrations. Molecular Pharmacology 93:3, pages 190-196.
Crossref
Crossref
Hui Chen, Hudan Liu & Guoliang Qing. (2018) Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduction and Targeted Therapy 3:1.
Crossref
Crossref
Ali Razaghi, Kirsten Heimann, Patrick M. Schaeffer & Spencer B. Gibson. (2018) Negative regulators of cell death pathways in cancer: perspective on biomarkers and targeted therapies. Apoptosis 23:2, pages 93-112.
Crossref
Crossref
F C Koyama, C M Lopes Ramos, F Ledesma, V A F Alves, J M Fernandes, B B Vailati, G P São Julião, A Habr-Gama, J Gama-Rodrigues, R O Perez & A A Camargo. (2018) Effect of Akt activation and experimental pharmacological inhibition on responses to neoadjuvant chemoradiotherapy in rectal cancer. British Journal of Surgery 105:2, pages e192-e203.
Crossref
Crossref
Shohei Miyata, Li-Yan Wang & Susumu Kitanaka. (2018) 3EZ, 20Ac-ingenol induces cell-specific apoptosis in cyclin D1 over-expression through the activation of ATR and downregulation of p-Akt. Leukemia Research 64, pages 46-51.
Crossref
Crossref
Marco Túlio C. Pessôa, Leandro A. Barbosa & José Augusto F.P. Villar. 2018.
79
113
.
Christopher D. Suarez, Junmin Wu, Sunil S. Badve, Joseph A. Sparano, William Kaliney & Laurie E. Littlepage. (2017) The AKT inhibitor triciribine in combination with paclitaxel has order-specific efficacy against Zfp217-induced breast cancer chemoresistance. Oncotarget 8:65, pages 108534-108547.
Crossref
Crossref
Katharina Mueck, Simone Rebholz, Mozhgan Harati, H. Rodemann & Mahmoud Toulany. (2017) Akt1 Stimulates Homologous Recombination Repair of DNA Double-Strand Breaks in a Rad51-Dependent Manner. International Journal of Molecular Sciences 18:11, pages 2473.
Crossref
Crossref
Dezhi Yang, Dongdong Tong, Qian Zhang, Yongtao Wang, Jing Sun, Fenghe Zhang & Guisen Zhao. (2017) Design, synthesis, and evaluation of novel Akt1 inhibitors based on an indole scaffold. Chemical Biology & Drug Design 90:5, pages 791-803.
Crossref
Crossref
Jean Franciesco Vettorazzi, Mirian Ayumi Kurauti, Gabriela Moreira Soares, Patricia Cristine Borck, Sandra Mara Ferreira, Renato Chaves Souto Branco, Luciana de Souza Lima Michelone, Antonio Carlos Boschero, Jose Maria Costa Junior & Everardo Magalhães Carneiro. (2017) Bile acid TUDCA improves insulin clearance by increasing the expression of insulin-degrading enzyme in the liver of obese mice. Scientific Reports 7:1.
Crossref
Crossref
Santosh Philips, Heng-Yi Wu & Lang Li. (2017) Using machine learning algorithms to identify genes essential for cell survival. BMC Bioinformatics 18:S11.
Crossref
Crossref
Omer F. Kuzu, Raghavendra Gowda, Arati Sharma, Mohammad A. Noory, Saketh S. Dinavahi, Gregory Kardos, Joseph J. Drabick & Gavin P. Robertson. (2017) Improving pharmacological targeting of AKT in melanoma. Cancer Letters 404, pages 29-36.
Crossref
Crossref
Guanhua Rao, Mariaelena Pierobon, In-Kyu Kim, Wei-Hsun Hsu, Jianghong Deng, Yong-Wha Moon, Emanuel F. Petricoin, Yu-Wen Zhang, Yisong Wang & Giuseppe Giaccone. (2017) Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations. Scientific Reports 7:1.
Crossref
Crossref
Chunxian Zhou, Fengyun Cui, Jiali Li, Diyi Wang, Yingze Wei, Ying Wu, Jiping Wang, Hongguang Zhu & Shuyang Wang. (2017) MiR-650 represses high-risk non-metastatic colorectal cancer progression via inhibition of AKT2/GSK3β/E-cadherin pathway. Oncotarget 8:30, pages 49534-49547.
Crossref
Crossref
Bhumika Wadhwa, Ubaid Makhdoomi, Ram Vishwakarma & Fayaz Malik. (2017) Protein kinase B. Anti-Cancer Drugs 28:6, pages 569-580.
Crossref
Crossref
Rebecca A. Previs, Guillermo N. Armaiz-Pena, Cristina Ivan, Heather J. Dalton, Rajesha Rupaimoole, Jean M. Hansen, Yasmin Lyons, Jie Huang, Monika Haemmerle, Michael J. Wagner, Kshipra M. Gharpure, Archana S. Nagaraja, Justyna Filant, Michael H. McGuire, Kyunghee Noh, Piotr L. Dorniak, Sarah L. Linesch, Lingegowda S. Mangala, Sunila Pradeep, Sherry Y. Wu & Anil K. Sood. (2017) Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. JNCI: Journal of the National Cancer Institute 109:7.
Crossref
Crossref
S T Ribeiro, M Tesio, J C Ribot, E Macintyre, J T Barata & B Silva-Santos. (2016) Casein kinase 2 controls the survival of normal thymic and leukemic γδ T cells via promotion of AKT signaling. Leukemia 31:7, pages 1603-1610.
Crossref
Crossref
Jillian M. Silva, Marian M. Deuker, Bruce C. Baguley & Martin McMahon. (2017)
PIK3CA
-mutated melanoma cells rely on cooperative signaling through mTORC1/2 for sustained proliferation
. Pigment Cell & Melanoma Research 30:3, pages 353-367.
Crossref
Crossref
Kwang Il Park, Hyeonsoo Park, Arulkumar Nagappan, Gyeong Eun Hong, Silvia Yumnam, Ho Jeong Lee, Eun Hee Kim, Won Sup Lee, Sung Chul Shin, Jin A Kim, Sang Joon Lee, Jin Yeul Ma, Taesun Min, Jeong Doo Heo & Gon Sup Kim. (2017) Polyphenolic compounds from Korean Lonicera japonica Thunb. induces apoptosis via AKT and caspase cascade activation in A549 cells. Oncology Letters 13:4, pages 2521-2530.
Crossref
Crossref
Oliver Politz, Franziska Siegel, Lars Bärfacker, Ulf Bömer, Andrea Hägebarth, William J. Scott, Martin Michels, Stuart Ince, Roland Neuhaus, Kirstin Meyer, Amaury Ernesto Fernández-Montalván, Ningshu Liu, Franz von Nussbaum, Dominik Mumberg & Karl Ziegelbauer. (2017) BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models. International Journal of Cancer 140:2, pages 449-459.
Crossref
Crossref
T. Harshani Peiris, Daniel Ramirez, Paul G. Barghouth & Néstor J. Oviedo. (2016) The Akt signaling pathway is required for tissue maintenance and regeneration in planarians. BMC Developmental Biology 16:1.
Crossref
Crossref
Timothy P. Heffron. (2016) Small Molecule Kinase Inhibitors for the Treatment of Brain Cancer. Journal of Medicinal Chemistry 59:22, pages 10030-10066.
Crossref
Crossref
Sara H�ggblad Sahlberg, Anja Mortensen, Jakob Hagl�f, Mikael Engskog, Torbj�rn Arvidsson, Curt Pettersson, Bengt Glimelius, Bo Stenerl�w & Marika Nestor. (2016) Different functions of AKT1 and AKT2 in molecular pathways, cell migration and metabolism in colon cancer cells. International Journal of Oncology.
Crossref
Crossref
Prabhjot S. Mundi, Jasgit Sachdev, Carolyn McCourt & Kevin Kalinsky. (2016) AKT in cancer: new molecular insights and advances in drug development. British Journal of Clinical Pharmacology 82:4, pages 943-956.
Crossref
Crossref
Sara S. Franco, Karolina Szczesna, Maria S. Iliou, Mohammed Al-Qahtani, Ali Mobasheri, Julianna Kobolák & András Dinnyés. (2016) In vitro models of cancer stem cells and clinical applications. BMC Cancer 16:S2.
Crossref
Crossref
Simone Laura Schulte, Andreas Waha, Barbara Steiger, Dorota Denkhaus, Evelyn Dörner, Gabriele Calaminus, Ivo Leuschner & Torsten Pietsch. (2016) CNS germinomas are characterized by global demethylation, chromosomal instability and mutational activation of the Kit-, Ras/Raf/Erk- and Akt-pathways. Oncotarget 7:34, pages 55026-55042.
Crossref
Crossref
Wenhu Zhan, Lei Xu, Xiaowu Dong, Jun Dong, Xiao Yi, Xiaodong Ma, Ni Qiu, Jia Li, Bo Yang, Yubo Zhou & Yongzhou Hu. (2016) Design, synthesis and biological evaluation of pyrazol-furan carboxamide analogues as novel Akt kinase inhibitors. European Journal of Medicinal Chemistry 117, pages 47-58.
Crossref
Crossref
Beibei Zhai, Xiaofeng Zhang, Bin Sun, Lu Cao, Linlin Zhao, Jun Li, Naijian Ge, Lei Chen, Haihua Qian & Zhengfeng Yin. (2015) MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK. Tumor Biology 37:6, pages 8047-8055.
Crossref
Crossref
Uddhav Timilsina & Ritu Gaur. (2016) Modulation of apoptosis and viral latency – an axis to be well understood for successful cure of human immunodeficiency virus. Journal of General Virology 97:4, pages 813-824.
Crossref
Crossref
Chia-Wei Li, Weiya Xia, Seung-Oe Lim, Jennifer L. Hsu, Longfei Huo, Yun Wu, Long-Yuan Li, Chien-Chen Lai, Shih-Shin Chang, Yi-Hsin Hsu, Hui-Lung Sun, Jongchan Kim, Hirohito Yamaguchi, Dung-Fang Lee, Hongmei Wang, Yan Wang, Chao-Kai Chou, Jung-Mao Hsu, Yun-Ju Lai, Adam M. LaBaff, Qingqing Ding, How-Wen Ko, Fuu-Jen Tsai, Chang-Hai Tsai, Gabriel N. Hortobagyi & Mien-Chie Hung. (2016) AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation. Cancer Research 76:6, pages 1451-1462.
Crossref
Crossref
Guanyu Wang. (2016) Chemoinformatics in the New Era: From Molecular Dynamics to Systems Dynamics. Molecules 21:3, pages 71.
Crossref
Crossref
Zheng Yang, Nianyu Huang, Bang Xu, Wenfeng Huang, Tianpeng Xie, Fan Cheng & Kun Zou. (2016) Cytotoxic 1,3-Thiazole and 1,2,4-Thiadiazole Alkaloids from Penicillium oxalicum: Structural Elucidation and Total Synthesis. Molecules 21:3, pages 232.
Crossref
Crossref
Lydia WT Cheung & Gordon B Mills. (2016)
Targeting therapeutic liabilities engendered by
PIK3R1
mutations for cancer treatment
. Pharmacogenomics 17:3, pages 297-307.
Crossref
Crossref
Tongzheng Liu, Yuan Fang, Haoxing Zhang, Min Deng, Bowen Gao, Nifang Niu, Jia Yu, SeungBaek Lee, JungJin Kim, Bo Qin, Fang Xie, Debra Evans, Liewei Wang, Wenhui Lou & Zhenkun Lou. (2016) HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy. Cancer Research 76:3, pages 572-581.
Crossref
Crossref
Astrid Grottke, Florian Ewald, Tobias Lange, Dominik Nörz, Christiane Herzberger, Johanna Bach, Nicole Grabinski, Lareen Gräser, Frank Höppner, Björn Nashan, Udo Schumacher & Manfred Jücker. (2016) Downregulation of AKT3 Increases Migration and Metastasis in Triple Negative Breast Cancer Cells by Upregulating S100A4. PLOS ONE 11:1, pages e0146370.
Crossref
Crossref
Goutam Dey, Rashmi Bharti, Indranil Banerjee, Anjan Kumar Das, Chandan Kanta Das, Subhayan Das, Bikash Chandra Jena, Mridula Misra, Ramkrishna Sen & Mahitosh Mandal. (2016) Pre-clinical risk assessment and therapeutic potential of antitumor lipopeptide ‘Iturin A’ in an in vivo and in vitro model. RSC Advances 6:75, pages 71612-71623.
Crossref
Crossref
Kristin Werner, Detlef Neumann & Roland Seifert. (2015) High constitutive Akt2 activity in U937 promonocytes: effective reduction of Akt2 phosphorylation by the histamine H2-receptor and the β2-adrenergic receptor. Naunyn-Schmiedeberg's Archives of Pharmacology 389:1, pages 87-101.
Crossref
Crossref
Shilpa Bhatia, Kellen Hirsch, Nimrah A. Baig, Olga Rodriguez, Olga Timofeeva, Kevin Kavanagh, Yi Chien Lee, Xiao-Jing Wang, Christopher Albanese & Sana D. Karam. (2015) Effects of altered ephrin-A5 and EphA4/EphA7 expression on tumor growth in a medulloblastoma mouse model. Journal of Hematology & Oncology 8:1.
Crossref
Crossref
Shilpa Gupta, Guillem Argilés, Pamela N. Munster, Antoine Hollebecque, Olav Dajani, Jonathan D. Cheng, Ruixue Wang, Ann Swift, Alessandra Tosolini & Sarina A. Piha-Paul. (2015) A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies. Clinical Cancer Research 21:23, pages 5235-5244.
Crossref
Crossref
Aurélie Auguste, Laurianne Bessière, Anne-Laure Todeschini, Sandrine Caburet, Sabine Sarnacki, Jaime Prat, Emanuela D'angelo, Pierre De La Grange, Olivier Ariste, Fréderic Lemoine, Bérangère Legois, Charles Sultan, Alain Zider, Louise Galmiche, Nicolas Kalfa & Reiner A. Veitia. (2015)
Molecular analyses of juvenile granulosa cell tumors bearing
AKT1
mutations provide insights into tumor biology and therapeutic leads
. Human Molecular Genetics 24:23, pages 6687-6698.
Crossref
Crossref
Yi Yu, Ronald E. Savage, Sudharshan Eathiraj, Justin Meade, Michael J. Wick, Terence Hall, Giovanni Abbadessa & Brian Schwartz. (2015) Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092. PLOS ONE 10:10, pages e0140479.
Crossref
Crossref
Saketh S. Dinavahi, Rajagopalan Prasanna, Sriram Dharmarajan, Yogeeswari Perumal & Srikant Viswanadha. (2015) A Novel, Potent, Small Molecule AKT Inhibitor Exhibits Efficacy against Lung Cancer Cells <i>In Vitro</i>. Cancer Research and Treatment 47:4, pages 913-920.
Crossref
Crossref
Sharon L. Eddie, Suzanne M. Quartuccio, Eoghainin Ó hAinmhire, Georgette Moyle-Heyrman, Dan D. Lantvit, Jian-Jun Wei, Barbara C. Vanderhyden & Joanna E. Burdette. (2015) Tumorigenesis and peritoneal colonization from fallopian tube epithelium. Oncotarget 6:24, pages 20500-20512.
Crossref
Crossref
Lisandra E. de Castro Brás. (2015) Osteopontin: A major player on hypertension-induced vascular remodeling. Journal of Molecular and Cellular Cardiology 85, pages 151-152.
Crossref
Crossref
Anindya Chatterjee, Joydeep Ghosh & Reuben Kapur. (2015) Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder. Oncotarget 6:21, pages 18250-18264.
Crossref
Crossref
Ramesh K. Ramanathan, Shannon L. McDonough, Hagen F. Kennecke, Syma Iqbal, Joaquina C. Baranda, Tara E. Seery, Howard J. Lim, Aram F. Hezel, Gina M. Vaccaro & Charles D. Blanke. (2015) Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005). Cancer 121:13, pages 2193-2197.
Crossref
Crossref
G. Xue, A. Zippelius, A. Wicki, M. Mandala, F. Tang, D. Massi & B. A. Hemmings. (2015) Integrated Akt/PKB Signaling in Immunomodulation and Its Potential Role in Cancer Immunotherapy. JNCI Journal of the National Cancer Institute 107:7, pages djv171-djv171.
Crossref
Crossref
Katarzyna B. Leszczynska, Iosifina P. Foskolou, Aswin G. Abraham, Selvakumar Anbalagan, Céline Tellier, Syed Haider, Paul N. Span, Eric E. O’Neill, Francesca M. Buffa & Ester M. Hammond. (2015) Hypoxia-induced p53 modulates both apoptosis and radiosensitivity via AKT. Journal of Clinical Investigation 125:6, pages 2385-2398.
Crossref
Crossref
Joanne Ngeow & Charis Eng. (2015) PTEN hamartoma tumor syndrome: Clinical risk assessment and management protocol. Methods 77-78, pages 11-19.
Crossref
Crossref
Hui Jun Lim, Philip Crowe & Jia-Lin Yang. (2014) Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer. Journal of Cancer Research and Clinical Oncology 141:4, pages 671-689.
Crossref
Crossref
Ribai Yan, Hsiao-Ching Chuang, Naval Kapuriya, Chih-Chien Chou, Po-Ting Lai, Hsin-Wen Chang, Chia-Ning Yang, Samuel K. Kulp & Ching-Shih Chen. (2015) Exploitation of the Ability of γ-Tocopherol to Facilitate Membrane Co-localization of Akt and PHLPP1 to Develop PHLPP1-Targeted Akt Inhibitors. Journal of Medicinal Chemistry 58:5, pages 2290-2298.
Crossref
Crossref
Han-Li Huang, Chieh-Yu Peng, Mei-Jung Lai, Chun-Han Chen, Hsueh-Yun Lee, Jing-Chi Wang, Jing-Ping Liou, Shiow-Lin Pan & Che-Ming Teng. (2014)
Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma
in vitro
and
in vivo
. Oncotarget 6:7, pages 4976-4991.
Crossref
Crossref
L Jiang, P Dong, Z Zhang, C Li, Y Li, Y Liao, X Li, Z Wu, S Guo, S Mai, D Xie, Z Liu & F Zhou. (2015) Akt phosphorylates Prohibitin 1 to mediate its mitochondrial localization and promote proliferation of bladder cancer cells. Cell Death & Disease 6:2, pages e1660-e1660.
Crossref
Crossref
R Brown, S Yang, C Weatherburn, J Gibson, P J Ho, H Suen, D Hart & D Joshua. (2014) Phospho-flow detection of constitutive and cytokine-induced pSTAT3/5, pAKT and pERK expression highlights novel prognostic biomarkers for patients with multiple myeloma. Leukemia 29:2, pages 483-490.
Crossref
Crossref
Olga V. Plotnikova, Seongjin Seo, Denny L. Cottle, Sarah Conduit, Sandra Hakim, Jennifer M. Dyson, Christina A. Mitchell & Ian M. Smyth. (2015) INPP5E interacts with AURKA, linking phosphoinositide signaling to primary cilium stability. Journal of Cell Science 128:2, pages 364-372.
Crossref
Crossref
Zu-Yao Yang, Meng-Yang Di, Jin-Qiu Yuan, Wei-Xi Shen, Da-Yong Zheng, Jin-Zhang Chen, Chen Mao & Jin-Ling Tang. (2015) The prognostic value of phosphorylated Akt in breast cancer: a systematic review. Scientific Reports 5:1.
Crossref
Crossref
Aarti N. Desai & Abhay Jere. 2015. Next Generation Sequencing in Cancer Research, Volume 2. Next Generation Sequencing in Cancer Research, Volume 2
103
125
.
Luis León, Enrique Grande & Luis Antón-Aparicio. 2015. Targeted Therapies for Solid Tumors. Targeted Therapies for Solid Tumors
127
135
.
David Olagnier, Alexandre Sze, Samar Bel Hadj, Cindy Chiang, Courtney Steel, Xiaoying Han, Jean-Pierre Routy, Rongtuan Lin, John Hiscott & Julien van Grevenynghe. (2014) HTLV-1 Tax-Mediated Inhibition of FOXO3a Activity Is Critical for the Persistence of Terminally Differentiated CD4+ T Cells. PLoS Pathogens 10:12, pages e1004575.
Crossref
Crossref
Marion Morel, Mathieu Vanderstraete, Katia Cailliau, Arlette Lescuyer, Julien Lancelot & Colette Dissous. (2014) Compound library screening identified Akt/PKB kinase pathway inhibitors as potential key molecules for the development of new chemotherapeutics against schistosomiasis. International Journal for Parasitology: Drugs and Drug Resistance 4:3, pages 256-266.
Crossref
Crossref
Florian Ewald, Dominik Nörz, Astrid Grottke, Bianca T. Hofmann, Björn Nashan & Manfred Jücker. (2014) Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors. Investigational New Drugs 32:6, pages 1144-1154.
Crossref
Crossref
P Dahan, J Martinez Gala, C Delmas, S Monferran, L Malric, D Zentkowski, V Lubrano, C Toulas, E Cohen-Jonathan Moyal & A Lemarie. (2014) Ionizing radiations sustain glioblastoma cell dedifferentiation to a stem-like phenotype through survivin: possible involvement in radioresistance. Cell Death & Disease 5:11, pages e1543-e1543.
Crossref
Crossref
Z A Antonello & C Nucera. (2013) Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAFV600E or wild-type BRAF. Oncogene 33:47, pages 5397-5404.
Crossref
Crossref
Mohd Rehan, Mohd A. Beg, Shadma Parveen, Ghazi A. Damanhouri & Galila F. Zaher. (2014) Computational Insights into the Inhibitory Mechanism of Human AKT1 by an Orally Active Inhibitor, MK-2206. PLoS ONE 9:10, pages e109705.
Crossref
Crossref
Benjamin Trinité, Chi N. Chan, Caroline S. Lee, Saurabh Mahajan, Yang Luo, Mark A. Muesing, Joy M. Folkvord, Michael Pham, Elizabeth Connick & David N. Levy. (2014) Suppression of Foxo1 Activity and Down-Modulation of CD62L (L-Selectin) in HIV-1 Infected Resting CD4 T Cells. PLoS ONE 9:10, pages e110719.
Crossref
Crossref
A. Kleger, L. Perkhofer & T. Seufferlein. (2014) Smarter drugs emerging in pancreatic cancer therapy. Annals of Oncology 25:7, pages 1260-1270.
Crossref
Crossref
Marina Gálvez-Peralta, Karen S. Flatten, David A. Loegering, Kevin L. Peterson, Paula A. Schneider, Charles Erlichman & Scott H. Kaufmann. (2014) Context-Dependent Antagonism between Akt Inhibitors and Topoisomerase Poisons. Molecular Pharmacology 85:5, pages 723-734.
Crossref
Crossref
Jiri PolivkaJr.Jr. & Filip Janku. (2014) Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacology & Therapeutics 142:2, pages 164-175.
Crossref
Crossref
Camillo Porta, Chiara Paglino & Alessandra Mosca. (2014) Targeting PI3K/Akt/mTOR Signaling in Cancer. Frontiers in Oncology 4.
Crossref
Crossref
Sandra W Cowan-JacobWolfgang Jahnke & Stefan Knapp. (2014) Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases. Future Medicinal Chemistry 6:5, pages 541-561.
Crossref
Crossref
Emmanuel Chautard, Zangbéwendé Guy Ouédraogo, Julian Biau & Pierre Verrelle. (2014) Role of Akt in human malignant glioma: from oncogenesis to tumor aggressiveness. Journal of Neuro-Oncology 117:2, pages 205-215.
Crossref
Crossref
F Yang, R Deng, X-J Qian, S-H Chang, X-Q Wu, J Qin, G-K Feng, K Ding & X-F Zhu. (2014) Feedback loops blockade potentiates apoptosis induction and antitumor activity of a novel AKT inhibitor DC120 in human liver cancer. Cell Death & Disease 5:3, pages e1114-e1114.
Crossref
Crossref
Jillian M. Silva, Christina Bulman & Martin McMahon. (2014) BRAFV600E Cooperates with PI3K Signaling, Independent of AKT, to Regulate Melanoma Cell Proliferation. Molecular Cancer Research 12:3, pages 447-463.
Crossref
Crossref
David A. Fruman & Christian Rommel. (2014) PI3K and cancer: lessons, challenges and opportunities. Nature Reviews Drug Discovery 13:2, pages 140-156.
Crossref
Crossref
Dongmei Ji, Zhe Zhang, Lei Cheng, Jinjia Chang, Shanshan Wang, Biqiang Zheng, Rongliang Zheng, Zuojun Sun, Chenchen Wang, Zhiqing Zhang, Rujiao Liu, Xiaowei Zhang, Xin Liu, Xiaofeng Wang & Jin Li. (2014) The Combination of RAD001 and MK-2206 Exerts Synergistic Cytotoxic Effects against PTEN Mutant Gastric Cancer Cells: Involvement of MAPK-Dependent Autophagic, but Not Apoptotic Cell Death Pathway. PLoS ONE 9:1, pages e85116.
Crossref
Crossref
Armin Bauer & Mark Brönstrup. (2014) Industrial natural product chemistry for drug discovery and development. Nat. Prod. Rep. 31:1, pages 35-60.
Crossref
Crossref
Dezhi Yang, Peng Wang, Jianzhen Liu, Hualu Xing, Yang Liu, Wencheng Xie & Guisen Zhao. (2014) Design, synthesis and evaluation of novel indole derivatives as AKT inhibitors. Bioorganic & Medicinal Chemistry 22:1, pages 366-373.
Crossref
Crossref
A. Mortlock, K. Foote, J. Kettle & B. Aquila. 2014. Reference Module in Chemistry, Molecular Sciences and Chemical Engineering. Reference Module in Chemistry, Molecular Sciences and Chemical Engineering.
Zahid H. Siddik. 2014. Cancer Drug Design and Discovery. Cancer Drug Design and Discovery
357
390
.
Haitao Meng, Yingming Jin, Hui Liu, Liangshun You, Chunmei Yang, Xue Yang & Wenbin Qian. (2013) SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt. Journal of Hematology & Oncology 6:1.
Crossref
Crossref
Jaikrit Bhutani, Asfandyar Sheikh & Asfandyar Khan Niazi. (2013) Akt inhibitors: mechanism of action and implications for anticancer therapeutics. Infectious Agents and Cancer 8:1.
Crossref
Crossref
Florian Ewald, Nicole Grabinski, Astrid Grottke, Sabine Windhorst, Dominik Nörz, Lisa Carstensen, Katharina Staufer, Bianca T. Hofmann, Frank Diehl, Kerstin David, Udo Schumacher, Björn Nashan & Manfred Jücker. (2013) Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma. International Journal of Cancer 133:9, pages 2065-2076.
Crossref
Crossref
Ana Marta Matos & Ana Paula Francisco. (2013) Targets, Structures, and Recent Approaches in Malignant Melanoma Chemotherapy. ChemMedChem 8:11, pages 1751-1765.
Crossref
Crossref
Giuseppe Giaccone & Jean-Charles SoriaSimona Wagner & Janet Dancey. 2013. Targeted Therapies in Oncology, Second Edition. Targeted Therapies in Oncology, Second Edition
81
114
.
Yanyuan Wu, Marianna Sarkissyan, Yahya Elshimali & Jaydutt V. Vadgama. (2013) Triple Negative Breast Tumors in African-American and Hispanic/Latina Women Are High in CD44+, Low in CD24+, and Have Loss of PTEN. PLoS ONE 8:10, pages e78259.
Crossref
Crossref
Kiran Mahajan & Nupam P. Mahajan. (2013) ACK1 tyrosine kinase: Targeted inhibition to block cancer cell proliferation. Cancer Letters 338:2, pages 185-192.
Crossref
Crossref
Fiona Pachl, Patrik Plattner, Benjamin Ruprecht, Guillaume Médard, Norbert Sewald & Bernhard Kuster. (2013) Characterization of a Chemical Affinity Probe Targeting Akt Kinases. Journal of Proteome Research 12:8, pages 3792-3800.
Crossref
Crossref
Siguang Xu, Shunqiang Li, Zhanfang Guo, Jingqin Luo, Matthew J. Ellis & Cynthia X. Ma. (2013) Combined Targeting of mTOR and AKT Is an Effective Strategy for Basal-like Breast Cancer in Patient-Derived Xenograft Models. Molecular Cancer Therapeutics 12:8, pages 1665-1675.
Crossref
Crossref
Yasuyuki Gen, Kohichiroh Yasui, Taichiro Nishikawa & Toshikazu Yoshikawa. (2013)
SOX
2 promotes tumor growth of esophageal squamous cell carcinoma through the
AKT
/mammalian target of rapamycin complex 1 signaling pathway
. Cancer Science 104:7, pages 810-816.
Crossref
Crossref
Emma E. Vincent, Douglas J. E. Elder, Jon Curwen, Elaine Kilgour, Ingeborg Hers & Jeremy M. Tavaré. (2013) Targeting Non-Small Cell Lung Cancer Cells by Dual Inhibition of the Insulin Receptor and the Insulin-Like Growth Factor-1 Receptor. PLoS ONE 8:6, pages e66963.
Crossref
Crossref
Alexander Arlt, Susanne Sebens Müerköster & Heiner Schäfer. (2013) Targeting apoptosis pathways in pancreatic cancer. Cancer Letters 332:2, pages 346-358.
Crossref
Crossref
Marloes Wennemers, Hanneke Stegeman, Johan Bussink, Yvonne M.H. Versleijen-Jonkers, Hanneke W.M van Laarhoven, James A. Raleigh, Mahesh A. Varia, Fred C.G.J. Sweep & Paul N. Span. (2018) Hypoxia Regulation of Phosphokinases and the Prognostic Value of pAKT in Breast Cancer. The International Journal of Biological Markers 28:2, pages 151-160.
Crossref
Crossref
Jie Lin, Deepak Sampath, Michelle A. Nannini, Brian B. Lee, Michael Degtyarev, Jason Oeh, Heidi Savage, Zhengyu Guan, Rebecca Hong, Robert Kassees, Leslie B. Lee, Tyler Risom, Stefan Gross, Bianca M. Liederer, Hartmut Koeppen, Nicholas J. Skelton, Jeffrey J. Wallin, Marcia Belvin, Elizabeth Punnoose, Lori S. Friedman & Kui Lin. (2013) Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models. Clinical Cancer Research 19:7, pages 1760-1772.
Crossref
Crossref
Atsushi Kato, Kathryn E. Hulse, Bruce K. Tan & Robert P. Schleimer. (2013) B-lymphocyte lineage cells and the respiratory system. Journal of Allergy and Clinical Immunology 131:4, pages 933-957.
Crossref
Crossref
Mary Catherine Reneer & Francesc Marti. (2012) The balancing act of AKT in T cells. Frontiers in Biology 8:2, pages 160-174.
Crossref
Crossref
Matt Addie, Peter Ballard, David Buttar, Claire Crafter, Gordon Currie, Barry R. Davies, Judit Debreczeni, Hannah Dry, Philippa Dudley, Ryan Greenwood, Paul D. Johnson, Jason G. Kettle, Clare Lane, Gillian Lamont, Andrew Leach, Richard W. A. Luke, Jeff Morris, Donald Ogilvie, Ken Page, Martin Pass, Stuart Pearson & Linette Ruston. (2013)
Discovery of 4-Amino-
N
-[(1
S
)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7
H
-pyrrolo[2,3-
d
]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an Orally Bioavailable, Potent Inhibitor of Akt Kinases
. Journal of Medicinal Chemistry 56:5, pages 2059-2073.
Crossref
Crossref
Kristen M. Smith & Catriona H. M. Jamieson. 2006. Encyclopedia of Molecular Cell Biology and Molecular Medicine. Encyclopedia of Molecular Cell Biology and Molecular Medicine.
Kui Lin. (2013) The Akt DUBbed InAktive. Science Signaling 6:257.
Crossref
Crossref
Michael P. Smith, Jennifer Ferguson, Imanol Arozarena, Robert Hayward, Richard Marais, Anna Chapman, Adam Hurlstone & Claudia Wellbrock. (2013) Effect of SMURF2 Targeting on Susceptibility to MEK Inhibitors in Melanoma. JNCI: Journal of the National Cancer Institute 105:1, pages 33-46.
Crossref
Crossref
Chiara Naro & Claudio Sette. (2013) Phosphorylation-Mediated Regulation of Alternative Splicing in Cancer. International Journal of Cell Biology 2013, pages 1-15.
Crossref
Crossref
Shailbala Singh, Sachin Shenoy, Pramod N. Nehete, Peiying Yang, Bharti Nehete, Danielle Fontenot, Guojun Yang, Robert A. Newman & K. Jagannadha Sastry. (2013) Nerium oleander derived cardiac glycoside oleandrin is a novel inhibitor of HIV infectivity. Fitoterapia 84, pages 32-39.
Crossref
Crossref
Alexander Kleger & Thomas Seufferlein. 2013. Erkrankungen des Pankreas. Erkrankungen des Pankreas
394
400
.
James A. McCubrey, Linda S. Steelman, William H. Chappell, Stephen L. Abrams, Richard A. Franklin, Giuseppe Montalto, Melchiorre Cervello, Ferdinando Nicoletti, Graziella Malaponte, Clorinda Massarino, Massimo Libra, Jörg Bäsecke, Agostino Tafuri, Michele Milella, Francesca Chiarini, Camilla Evangelisti, Lucio Cocco & Alberto M. Martelli. 2013. Cell Death Signaling in Cancer Biology and Treatment. Cell Death Signaling in Cancer Biology and Treatment
331
372
.
Nicole Grabinski, Florian Ewald, Bianca T Hofmann, Katharina Staufer, Udo Schumacher, Björn Nashan & Manfred Jücker. (2012) Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Molecular Cancer 11:1.
Crossref
Crossref
Chaitali ParikhVasantharajan JanakiramanWen-I Wu, Catherine K. FooNoelyn M. KljavinSubhra ChaudhuriEric StawiskiBrian LeeJie LinHong LiMaria N. LorenzoWenlin YuanJoseph GuilloryMarlena JacksonJesus RondonYvonne FrankeKrista K. BowmanMeredith SagollaJeremy StinsonThomas D. WuJiansheng WuDavid Stokoe, Howard M. SternBarbara J. Brandhuber, Kui LinNicholas J. Skelton & Somasekar Seshagiri. (2012) Disruption of PH–kinase domain interactions leads to oncogenic activation of AKT in human cancers. Proceedings of the National Academy of Sciences 109:47, pages 19368-19373.
Crossref
Crossref
Naveen Sharma, Edward B. Arias, Donel A. Sequea & Gregory D. Cartee. (2012) Preventing the calorie restriction-induced increase in insulin-stimulated Akt2 phosphorylation eliminates calorie restriction's effect on glucose uptake in skeletal muscle. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1822:11, pages 1735-1740.
Crossref
Crossref
James A. McCubrey, Linda S. Steelman, William H. Chappell, Stephen L. Abrams, Richard A. Franklin, Giuseppe Montalto, Melchiorre Cervello, Massimo Libra, Saverio Candido, Grazia Malaponte, Maria C. Mazzarino, Paolo Fagone, Ferdinando Nicoletti, Jörg Bäsecke, Sanja Mijatovic, Danijela Maksimovic-Ivanic, Michele Milella, Agostino Tafuri, Francesca Chiarini, Camilla Evangelisti, Lucio Cocco & Alberto M. Martelli. (2012) Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. Oncotarget 3:10, pages 1068-1111.
Crossref
Crossref
James F. Blake, Rui Xu, Josef R. Bencsik, Dengming Xiao, Nicholas C. Kallan, Stephen Schlachter, Ian S. Mitchell, Keith L. Spencer, Anna L. Banka, Eli M. Wallace, Susan L. Gloor, Matthew Martinson, Richard D. Woessner, Guy P.A. Vigers, Barbara J. Brandhuber, Jun Liang, Brian S. Safina, Jun Li, Birong Zhang, Christine Chabot, Steven Do, Leslie Lee, Jason Oeh, Deepak Sampath, Brian B. Lee, Kui Lin, Bianca M. Liederer & Nicholas J. Skelton. (2012) Discovery and Preclinical Pharmacology of a Selective ATP-Competitive Akt Inhibitor (GDC-0068) for the Treatment of Human Tumors. Journal of Medicinal Chemistry 55:18, pages 8110-8127.
Crossref
Crossref
KUSUMAWADEE UTISPAN, JUMAPORN SONONGBUA, PETI THUWAJIT, SIRI CHAU-IN, CHAWALIT PAIROJKUL, SOPIT WONGKHAM & CHANITRA THUWAJIT. (2012) Periostin activates integrin α5β1 through a PI3K/AKT-dependent pathway in invasion of cholangiocarcinoma. International Journal of Oncology 41:3, pages 1110-1118.
Crossref
Crossref
A Naing, C Aghajanian, E Raymond, D Olmos, G Schwartz, E Oelmann, L Grinsted, W Burke, R Taylor, S Kaye, R Kurzrock & U Banerji. (2012) Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma. British Journal of Cancer 107:7, pages 1093-1099.
Crossref
Crossref
Yinglin Zuo, Jianing Huang, Binhua Zhou, Shuni Wang, Weiyan Shao, Cuige Zhu, Li Lin, Gesi Wen, Hongyang Wang, Jun Du & Xianzhang Bu. (2012) Synthesis, cytotoxicity of new 4-arylidene curcumin analogues and their multi-functions in inhibition of both NF-κB and Akt signalling. European Journal of Medicinal Chemistry 55, pages 346-357.
Crossref
Crossref
Martin Schmidt-Hieber, Robert Dabrowski, Babette Aicher, Philipp Lohneis, Antonia Busse, Carola Tietze-Buerger, Birgit Reufi, Eckhard Thiel & Igor Wolfgang Blau. (2011) In vitro effects of perifosine, bortezomib and lenalidomide against hematopoietic progenitor cells from healthy donors. Investigational New Drugs 30:4, pages 1396-1403.
Crossref
Crossref
Alok Pant, Irene I. Lee, Zhenxiao Lu, Bo R. Rueda, Julian Schink & J. Julie Kim. (2012) Inhibition of AKT with the Orally Active Allosteric AKT Inhibitor, MK-2206, Sensitizes Endometrial Cancer Cells to Progestin. PLoS ONE 7:7, pages e41593.
Crossref
Crossref
Siqing Fu, Bryan T. Hennessy, Chaan S. Ng, Zhenlin Ju, Kevin R. Coombes, Judith K. Wolf, Anil K. Sood, Charles F. Levenback, Robert L. Coleman, John J. Kavanagh, David M. Gershenson, Maurie Markman, Kristine Dice, Adrienne Howard, Jane Li, Yang Li, Katherine Stemke-Hale, Mary Dyer, Edward Atkinson, Ed Jackson, Vikas Kundra, Razelle Kurzrock, Robert C. BastJr.Jr. & Gordon B. Mills. (2012) Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecologic Oncology 126:1, pages 47-53.
Crossref
Crossref
Pintipa Grongsaard, Paul G. Bulger, Debra J. Wallace, Lushi Tan, Qinghao Chen, Sarah J. Dolman, Jason Nyrop, R. Scott Hoerrner, Mark Weisel, Juan Arredondo, Takahiro Itoh, Chengfu Xie, Xianghui Wen, Dalian Zhao, Daniel J. Muzzio, Ephraim M. Bassan & C. Scott Shultz. (2012) Convergent, Kilogram Scale Synthesis of an Akt Kinase Inhibitor. Organic Process Research & Development 16:5, pages 1069-1081.
Crossref
Crossref
Wen-Bin Tsai, Isamu Aiba, Yan Long, Hui-Kuan Lin, Lynn Feun, Niramol Savaraj & Macus Tien Kuo. (2012) Activation of Ras/PI3K/ERK Pathway Induces c-Myc Stabilization to Upregulate Argininosuccinate Synthetase, Leading to Arginine Deiminase Resistance in Melanoma Cells. Cancer Research 72:10, pages 2622-2633.
Crossref
Crossref
Kui LinJie LinWen-I WuJoshua BallardBrian B. LeeSusan L. GloorGuy P. A. VigersTony H. MoralesLori S. FriedmanNicholas SkeltonBarbara J. Brandhuber. (2012) An ATP-Site On-Off Switch That Restricts Phosphatase Accessibility of Akt. Science Signaling 5:223.
Crossref
Crossref
Jason G. Kettle, Simon Brown, Claire Crafter, Barry R. Davies, Phillippa Dudley, Gary Fairley, Paul Faulder, Shaun Fillery, Hannah Greenwood, Janet Hawkins, Michael James, Keith Johnson, Clare D. Lane, Martin Pass, Jennifer H. Pink, Helen Plant & Sabina C. Cosulich. (2012) Diverse Heterocyclic Scaffolds as Allosteric Inhibitors of AKT. Journal of Medicinal Chemistry 55:3, pages 1261-1273.
Crossref
Crossref
NAOKO OKUMURA, HITOMI YOSHIDA, YURI NISHIMURA, YASUKO KITAGISHI & SATORU MATSUDA. (2012) Terpinolene, a component of herbal sage, downregulates AKT1 expression in K562 cells. Oncology Letters 3:2, pages 321-324.
Crossref
Crossref
Aiko OgawaAmy L. Firth, Kimberly A. SmithMary V. Maliakal & Jason X.-J. Yuan. (2012)
PDGF enhances store-operated Ca
2+
entry by upregulating STIM1/Orai1 via activation of Akt/mTOR in human pulmonary arterial smooth muscle cells
. American Journal of Physiology-Cell Physiology 302:2, pages C405-C411.
Crossref
Crossref
Naihan Xu, Yuanzhi Lao, Yaou Zhang & David A. Gillespie. (2012) Akt: A Double-Edged Sword in Cell Proliferation and Genome Stability. Journal of Oncology 2012, pages 1-15.
Crossref
Crossref
Felipe Ades & Otto Metzger-Filho. (2012) Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma. Dermatology Research and Practice 2012, pages 1-9.
Crossref
Crossref
Da-Zhi Liu & Bradley P. Ander. (2012) Cell Cycle Inhibition without Disruption of Neurogenesis Is a Strategy for Treatment of Aberrant Cell Cycle Diseases: An Update. The Scientific World Journal 2012, pages 1-13.
Crossref
Crossref
Shaohua Chang, Zhang Zhang, Xiaoxi Zhuang, Jinfeng Luo, Xianwen Cao, Honglin Li, Zhengchao Tu, Xiaoyun Lu, Xiaomei Ren & Ke Ding. (2012) New thiazole carboxamides as potent inhibitors of Akt kinases. Bioorganic & Medicinal Chemistry Letters 22:2, pages 1208-1212.
Crossref
Crossref
David Shahbazian, Joshua Sznol & Harriet M. Kluger. 2012. Current Challenges in Personalized Cancer Medicine. Current Challenges in Personalized Cancer Medicine
1
26
.
Michel Choueiri & Philip Mack. 2012. Kidney Cancer. Kidney Cancer
209
223
.
Samir Parekh, Marc A. Weniger & Adrian Wiestner. (2011) New molecular targets in mantle cell lymphoma. Seminars in Cancer Biology 21:5, pages 335-346.
Crossref
Crossref
Xinbo Zhang, Naimei Tang, Timothy J. Hadden & Arun K. Rishi. (2011) Akt, FoxO and regulation of apoptosis. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1813:11, pages 1978-1986.
Crossref
Crossref
Raquel De Souza, Payam Zahedi, Rose M. Badame, Christine Allen & Micheline Piquette-Miller. (2011) Chemotherapy Dosing Schedule Influences Drug Resistance Development in Ovarian Cancer. Molecular Cancer Therapeutics 10:7, pages 1289-1299.
Crossref
Crossref
Marc A. Weniger & Adrian Wiestner. (2011) Molecular Targeted Approaches in Mantle Cell Lymphoma. Seminars in Hematology 48:3, pages 214-226.
Crossref
Crossref
E E Vincent, D J E Elder, E C Thomas, L Phillips, C Morgan, J Pawade, M Sohail, M T May, M R Hetzel & J M Tavaré. (2011) Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancer. British Journal of Cancer 104:11, pages 1755-1761.
Crossref
Crossref
M. Christine Hollander, Gideon M. Blumenthal & Phillip A. Dennis. (2011) PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nature Reviews Cancer 11:4, pages 289-301.
Crossref
Crossref
Yerra Koteswara Rao, Alexander T. H. Wu, Madamanchi Geethangili, Ming-Te Huang, Wan-Ju Chao, Chih-Hsiung Wu, Win-Ping Deng, Chi-Tai Yeh & Yew-Min Tzeng. (2010) Identification of Antrocin from Antrodia camphorata as a Selective and Novel Class of Small Molecule Inhibitor of Akt/mTOR Signaling in Metastatic Breast Cancer MDA-MB-231 Cells. Chemical Research in Toxicology 24:2, pages 238-245.
Crossref
Crossref
Stacey A. Santi, Alison C. Douglas & Hoyun Lee. (2010) The Akt isoforms, their unique functions and potential as anticancer therapeutic targets. BioMolecular Concepts 1:5-6, pages 389-401.
Crossref
Crossref